Securing commercial supply increasingly requires more than access to large-scale capacity. It requires confidence that manufacturing can remain efficient, adaptable and compliant as demand, regulatory, quality and lifecycle requirements evolve.
In this Q&A, Jagruti Patel, Senior Director, Commercial Development, and Tillmann Schnierda, Senior Director, Manufacturing, explore how Lonza’s newest large-scale mammalian manufacturing facility in Visp combines six 20,000 L bioreactors with advanced automation, intensified manufacturing and experienced teams within an integrated Swiss biologics ecosystem.
Discover how the facility can help customers:
- Secure reliable commercial supply with operationally proven large-scale manufacturing and established quality systems
- Support evolving demand through multiproduct flexibility, conventional and intensified fed-batch capabilities, and access to a broader global network
- Reduce manufacturing variability through automation, electronic batch records and enhanced process-data visibility
- Simplify lifecycle execution by connecting process development, drug substance manufacturing, bioconjugation and drug product capabilities within the Swiss network
- Plan for long-term growth with experienced teams, integrated infrastructure and the flexibility to adapt supply strategies over time
